This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bobola, M. S. Articles by Goff, R. D. Search for Related Content PubMed PubMed Citation Articles by Bobola, M. S. Articles by Goff, R. D.

O⁶-Methylguanine-DNA Methyltransferase, O⁶-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines

Authors' Affiliations: ¹ Division of Neurosurgery; Departments of ² Surgery and ³ Hematology/Oncology, Children's Hospital and Regional Medical Center, Seattle, Washington; Departments of ³Neurological Surgery, ⁴ Pediatrics and ⁵ Pathology University of Washington, Seattle, Washington

Requests for reprints: Michael Bobola, Division of Neurosurgery, Department of Surgery, Children's Hospital and Regional Medical Center, Seattle, WA 98105. Phone: 206-987-2046; Fax: 206-987-7311; E-mail: michael.bobola{at}seattlechildrens.org.

Purpose: Primary brain tumors are the leading cause of cancer death in children. Our purpose is (a) to assess the contribution of the DNA repair protein O⁶-methylguanine-DNA methyltransferase (MGMT) to the resistance of pediatric brain tumor cell lines to clinical alkylating agents and (b) to evaluate variables for maximal potentiation of cell killing by the MGMT inhibitor O⁶-benzylguanine, currently in clinical trials. Few such data for pediatric glioma lines, particularly those from low-grade tumors, are currently available.

Experimental design: We used clonogenic assays of proliferative survival to quantitate cytoxicity of the chloroethylating agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and the methylating agent temozolomide in 11 glioma and five medulloblastoma lines. Twelve lines are newly established and characterized here, nine of them from low-grade gliomas including pilocytic astrocytomas.

Results: (a) MGMT is a major determinant of BCNU resistance and the predominant determinant of temozolomide resistance in both our glioma and medulloblastoma lines. On average, O⁶-benzylguanine reduced LD₁₀ for BCNU and temozolomide, 2.6- and 26-fold, respectively, in 15 MGMT-expressing lines. (b) O⁶-Benzylguanine reduced D_T (the threshold dose for killing) for BCNU and temozolomide, 3.3- and 138-fold, respectively. D_T was decreased from levels higher than, to levels below, clinically achievable plasma doses for both alkylators. (c) Maximal potentiation by O⁶-benzylguanine required complete and prolonged suppression of MGMT.

Conclusions: Our results support the use of O⁶-benzylguanine to achieve full benefit of alkylating agents, particularly temozolomide, in the chemotherapy of pediatric brain tumors.

Key Words: DNA repair • drug resistance • glioma • medulloblastoma • temozolomide

This article has been cited by other articles:

				T. Yamauchi, M. Ogawa, and T. Ueda Carmustine-Resistant Cancer Cells Are Sensitized to Temozolomide As A Result of Enhanced Mismatch Repair during the Development of Carmustine Resistance Mol. Pharmacol., July 1, 2008; 74(1): 82 - 91. [Abstract] [Full Text] [PDF]

				L. F.Z. Batista, W. P. Roos, M. Christmann, C. F.M. Menck, and B. Kaina Differential Sensitivity of Malignant Glioma Cells to Methylating and Chloroethylating Anticancer Drugs: p53 Determines the Switch by Regulating xpc, ddb2, and DNA Double-Strand Breaks Cancer Res., December 15, 2007; 67(24): 11886 - 11895. [Abstract] [Full Text] [PDF]

				A. Broniscer, S. Gururangan, T. J. MacDonald, S. Goldman, R. J. Packer, C. F. Stewart, D. Wallace, M. K. Danks, H. S. Friedman, T. Y. Poussaint, et al. Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report Clin. Cancer Res., November 15, 2007; 13(22): 6712 - 6718. [Abstract] [Full Text] [PDF]

				L. M. Wagner, R. E. McLendon, K. J. Yoon, B. D. Weiss, C. A. Billups, and M. K. Danks Targeting Methylguanine-DNA Methyltransferase in the Treatment of Neuroblastoma Clin. Cancer Res., September 15, 2007; 13(18): 5418 - 5425. [Abstract] [Full Text] [PDF]

				S. Gururangan, M. J. Fisher, J. C. Allen, J. E. Herndon II, J. A. Quinn, D. A. Reardon, J. J. Vredenburgh, A. Desjardins, P. C. Phillips, M. A. Watral, et al. Temozolomide in Children with progressive low-grade glioma Neuro-oncol, April 1, 2007; 9(2): 161 - 168. [Abstract] [Full Text] [PDF]

				M. S. Bobola, S. Varadarajan, N. W. Smith, R. D. Goff, D. D. Kolstoe, A. Blank, B. Gold, and J. R. Silber Human Glioma Cell Sensitivity to the Sequence-Specific Alkylating Agent Methyl-Lexitropsin Clin. Cancer Res., January 15, 2007; 13(2): 612 - 620. [Abstract] [Full Text] [PDF]

				N. A. Butowski, P. K. Sneed, and S. M. Chang Diagnosis and Treatment of Recurrent High-Grade Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1273 - 1280. [Abstract] [Full Text] [PDF]

				M. S. Bobola, L. S. Finn, R. G. Ellenbogen, J. R. Geyer, M. S. Berger, J. M. Braga, E. H. Meade, M. E. Gross, and J. R. Silber Apurinic/Apyrimidinic Endonuclease Activity Is Associated with Response to Radiation and Chemotherapy in Medulloblastoma and Primitive Neuroectodermal Tumors Clin. Cancer Res., October 15, 2005; 11(20): 7405 - 7414. [Abstract] [Full Text] [PDF]